One step forward for serelaxin as a promising therapy in cardiac fibrosis

Hypertension

Volumn 64, Issue 2, 2014, Pages 229-230

  Fernández Alfonso, María S ^a   Ruilope, Luis Miguel ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGENASE 3; ENALAPRIL; GELATINASE A; NITRIC OXIDE; SERELAXIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1;

BLOOD PRESSURE; CELL DIFFERENTIATION; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DRUG EFFICACY; FIBROBLAST; HEART MUSCLE FIBROSIS; HUMAN; MYOFIBROBLAST; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STAINING; UPREGULATION;

ANIMALS; BLOOD PRESSURE; ENALAPRIL; HEART; HEART DISEASES; MALE; RECOMBINANT PROTEINS; RELAXIN;

EID: 84904471979     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03642     Document Type: Note

References (9)

1. González A, Ravassa S, Beaumont J, López B, Díez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol. 2011;58:1833-1843.
2. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardiovascular effects of relaxin: From basic science to clinical therapy. Nat Rev Cardiol. 2010;7:48-58.
3. Metra M, Cotter G, Davison BA, et al; RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: Correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206.
4. Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension. 2014;64:315-322.
5. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184-195.
6. Mookerjee I, Hewitson TD, Halls ML, Summers RJ, Mathai ML, Bathgate RA, Tregear GW, Samuel CS. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 2009;23:1219-1229.
7. Zhang HY, Phan SH. Inhibition of myofibroblast apoptosis by transforming growth factor beta(1). Am J Respir Cell Mol Biol. 1999;21:658-665.
8. Dschietzig T, Bartsch C, Greinwald M, Baumann G, Stangl K. The pregnancy hormone relaxin binds to and activates the human glucocorticoid receptor. Ann N Y Acad Sci. 2005;1041:256-271.
9. Samuel CS, Unemori EN, Mookerjee I, Bathgate RA, Layfield SL, Mak J, Tregear GW, Du XJ. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145:4125-4133.